



Breakthrough Premature Ejaculation Treatment Fortacin™ to Launch Commercially in Continental Europe in Early 2018

Regent Pacific is in advanced stage negotiations to receive up to €41 million plus royalties pursuant to proposed amendments to its out-licence agreement with commercial partner Recordati

(14 August 2017, Hong Kong) – Regent Pacific Group Limited (“Regent Pacific” or the “Company” and together with its subsidiaries, the “Group”; Hong Kong stock code: 00575), a specialist healthcare and life sciences investment group, is pleased to announce that Recordati Group (“Recordati”) will now undertake the commercial launch of Regent’s flagship product Fortacin™ in Continental Europe in early 2018.

Regent Pacific’s out-licencing and commercial partner Recordati is expected to begin sales of Fortacin™ in France, Germany, Italy, Spain and Portugal in early 2018, and in the rest of Europe, Russia, the Commonwealth of Independent States (CIS) and select countries of North Africa in the coming years.

In addition, Regent Pacific is in advanced stage negotiations with Recordati to make certain amendments to its out-licence agreement between the Group and Recordati, pursuant to which it is intended that Regent Pacific’s wholly owned subsidiary Plethora Solutions Limited (“Solutions”) will also be eligible to receive payments of up to €41 million (US\$48 million/HK\$376 million) plus royalties after hitting certain milestones related to the Continental European roll-out.

Under the proposed amendments to its out-license agreement, Solutions would be eligible to receive:

- A payment of €4 million on the effective date of the amended out-license agreement;
- A payment of up to €4 million in total upon first commercial sales of the Fortacin™ product in France, Germany, Italy, Spain and Portugal (€800,000 for each of these 5 countries);
- A possible payment of up to €8 million in total, dependent on the net sales achieved by Recordati in the first 3 years of sales;
- Up to €25 million in aggregate in sales-based milestones; and
- Tiered percentage royalties on net sales, ranging from the mid-teens to the mid-twenties for 10 years from first commercial sale, and thereafter at a single digit percentage royalty rate

Fortacin™ is the first EU approved prescription treatment for premature ejaculation (“PE”) that does not act on the central nervous system and has been available in the UK by way of prescription since November 2016. The treatment is a topical spray containing low doses of two anaesthetics - lidocaine and prilocaine – that take effect almost immediately upon application, giving users more control without reducing pleasure.

Jamie Gibson, CEO of Regent Pacific said, “We’re very enthusiastic about our prospects for the second half of 2017. Regent Pacific also looks forward to the beginning of next year, when Recordati will begin rolling out Fortacin™ more broadly across Europe.”

Update on out-licensing

As previously disclosed, discussions and negotiations are continuing to take place in respect of out-licensing the grant of rights by Solutions with pharmaceutical companies and with other strategic partners in respect of Fortacin™ in other major territories outside of the UK and EU, including China. While it remains impossible to determine with accuracy the timing of completion of such agreements (and no assurance can be given that negotiations will lead to a binding licence agreement(s)), the Company anticipates that such discussions and negotiations will be assisted by Fortacin™ being brought to market in mainland Europe, which is expected to occur in early 2018. The Company will update shareholders and the market more generally if and when there are any relevant developments in this respect.

- END -

About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings plc, is a specialty pharmaceutical company whose core product Fortacin™ is the first EU approved topical prescription treatment for Premature Ejaculation that does not act on the central nervous system, launched in the UK in November 2016 and to be launched subsequently in Italy, Spain, France, Germany, Portugal, Czech Republic, Slovakia, Poland, Ireland, Romania and Greece, the rest of Europe, Russia, CIS and certain countries of North Africa. The Group has a strong track record of investments and has returned approximately US\$298 million to shareholders in the 19 years of financial reporting since its initial public offering.

For further information, please contact:**Finsbury**

Dan Simon (Hong Kong)

t : +852 3166 9868

e : dan.simon@finsbury.com

Alastair Hetherington (United Kingdom)

t: +44 20 7251 3801

e: alastair.hetherington@finsbury.com